Christopher Richard Anzalone

Chief Executive Officer

Christopher Richard Anzalone (Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Arrowhead Pharmaceuticals, Inc. (ARWR). The largest single filing was $12.2M of ARWR (181,832 sh across 9 lots, as filed), executed Dec 15 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$23.7M

shares × price, as filed

Last traded

Jan 2

Filed Jan 5

Median ADV $181.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $32.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

ARWR

Arrowhead Pharmaceuticals, Inc. ARWR · 0 buys · 11 sells 11 filings

Recent filings

ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $872K
13,187 sh across 2 lots
Exec Jan 2
Filed Jan 5 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $3.6M
51,726 sh across 2 lots
Exec Dec 29 2025
Filed Dec 30 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $1.7M
24,712 sh across 4 lots
Exec Dec 19 2025
Filed Dec 23 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $5.4M
84,018 sh across 3 lots
Exec Dec 17 2025
Filed Dec 19 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $12.2M
181,832 sh across 9 lots
Exec Dec 15 2025
Filed Dec 16 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $1.5M
136,105 sh across 3 lots
Exec Apr 9 2025
Filed Apr 11 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $775K
51,425 sh × $15.07
Exec Mar 13 2025
Filed Mar 17 2025 · 5:30 PM ET ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $5.3M
300,000 sh across 2 lots
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET More filings →